BOSTON, Mass. and VANCOUVER, British Columbia, October 8^th, 2026 – Alpha-9 Oncology Inc. (“Alpha-9”), a clinical-stage radiotherapeutic company developing targeted, next-generation treatments to meaningfully improve the lives of those living with cancer, today announced an upcoming oral presentation supporting the use of ⁶⁸Ga-A9-6217 PET/CT imaging in patients with gastrin-releasing peptide receptor (“GRPR”) expressing tumors at the European Association of Nuclear Medicine 2026 Annual Congress, taking place in Vienna, Austria, from October 17-21, 2026. 

Alpha-9 is currently enrolling a Phase 1 clinical trial evaluating safety, tolerability, and recommended dose for expansion of ²²⁵Ac-A9-0642 and ¹⁷⁷Lu-A9-0631 in patients with GRPR-positive solid tumors, including locally advanced, unresectable or metastatic HR+/HER2- breast cancer and other solid tumors. Alpha-9 is currently using its GRPR imaging agent, ⁶⁸Ga-A9-6217, for patient selection.

Oral Presentation Details:

Title: A Phase 1 Study Investigating the Safety, Biodistribution, and Dosimetry of [⁶⁸Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors: Case series of selected patients
Presentation Number: OP-877
Date/Time: Wednesday, October 21, 2026, 9:45 – 11:15 AM CEST, Hall C

Full abstracts are available online in the EANM’26 Abstract Book.

About Alpha-9 Oncology 

Alpha-9 Oncology is a clinical-stage radiotherapeutic company developing targeted, next-generation treatments to meaningfully improve the lives of people living with cancer. Our modular optimization process is designed to tailor each development candidate to the biological and biophysical characteristics of the tumor target and the selected radioisotope payload. We holistically engineer and optimize each component of our radiotherapeutics – the binder, linker, chelator, and radioisotope – to generate compounds which we believe will exhibit a wide therapeutic index through high tumor retention and low uptake in healthy organs. For more information, please visit www.a9oncology.com. 

Media Contact
Precision AQ
Alex Lobo
Alex.lobo@precisionaq.com